Skip to content

The study on the usefulness of fucoidan-containing food intake for early or unresectable advanced gastric cancer patients

The study on the usefulness of fucoidan-containing food intake for early or unresectable advanced gastric cancer patients - The study on the usefulness of fucoidan intake for gastric cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014461
Enrollment
30
Registered
2014-09-01
Start date
2014-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early or unresectable advanced gastric cancer

Interventions

To intake fucoidan-containing food every day.

Sponsors

Kyoto Prefectural University of Medicine
Lead Sponsor
TAKARA BIO, INC
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed gastric cancer. 2) Patients informed diagnosis of their disease. 3) Aged from 20 over years. 4) Grade 0 to 2 in performance status (ECOG). 5) In early gastric cancer patients, patients with confirmed the curative resection with endoscopic treatment. 6) In advanced gastric cancer patients, patients who are scheduled to newly primary chemotherapy. 7) Expected to be alive at least six months after informed consent in advanced gastric cancer patients. 8) Having written informed consent.

Exclusion criteria

Exclusion criteria: 1) Presence of severe complications (heart failure, liver desease, renal desease). 2) Presence of infectious disease. 3) Taking the drug affecting immune system such as steroid and immunosuppresant. 4) Taking the supplement affecting immune system. 5) Inappropriate patients for study judged by the physicians.

Design outcomes

Primary

MeasureTime frame
To assess immune monitoring such as cytokines, QOL evaluation and intestinal flora analysis.

Countries

Japan

Contacts

Public ContactYuji Naito

Kyoto Prefectural University of Medicine Molecular Gastroenterology and Hepatology

ynaito@koto.kpu-m.ac.jp075-251-5519

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026